Neenel Kharb, LMT Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 718 Haiku Rd, Haiku, HI 96708 Phone: 180-857-5988 Fax: 808-575-9888 |
Mary Fisk Dowdle, LMHC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 333 Manawai Place, Haiku, HI 96708 Phone: 703-675-3859 |
Joel Robert Schanker Counselor Medicare: Not Enrolled in Medicare Practice Location: 145 Mokupapa Rd, Haiku, HI 96708 Phone: 808-573-8373 |
Joshua William Harrison Akana Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 2912 E Lelehuna Pl, Haiku, HI 96708 Phone: 808-281-2842 |
Brien Benjamin, M.A. Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 222 Laniloa Way, Haiku, HI 96708 Phone: 303-883-5647 |
Savana Rose Campbell Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 65 E Waipio Rd, Haiku, HI 96708 Phone: 928-632-2121 |
News Archive
Starkey Laboratories, Inc., one of the world's leading hearing technology companies, is excited to introduce the S Series™ iQ OtoLens™, the world's first invisible-in-the-canal (IIC) hearing aid. OtoLens, a custom-molded hearing aid built using Starkey's Comfort Fit process, lives in the second bend of the ear, meaning that it is truly 100 percent invisible.
Sodium is essential for myriad biological processes including fluid balance and muscle contraction. However, too much sodium can have harmful effects such as increasing blood pressure.
The mathematical tool, quite used in Medical Physics, takes its name from the city of Montecarlo, well-known for its bingo halls and games of chance.
Pharmaceutical Institute, a leading provider of specialized training solutions for the pharmaceutical and biotech industry and a subsidiary of Campbell Alliance, today announced the release of Therapeutic Area Essentials™, a comprehensive suite of more than 155 therapeutic area e-courses covering diagnosis, cause, and treatment for over 40 disease states.
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tofacitinib (development code CP-690,550), an investigational novel, oral JAK inhibitor being studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis.
› Verified 1 days ago